References
[1] Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8_Supplement): 5467-5467.